- Investing Ideas
- /
- Taiwanese Pharmaceuticals & Biotech Undervalued based on future growth
Taiwanese Pharmaceuticals & Biotech Undervalued based on future growth
Results
3
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
3 companies
PharmaEssentia
Market Cap: NT$189.4b
A biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally.
6446
NT$512.00
7D
3.4%
1Y
-21.3%
Lotus Pharmaceutical
Market Cap: NT$76.9b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$292.50
7D
3.7%
1Y
10.0%
Bora Pharmaceuticals
Market Cap: NT$64.1b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$517.00
7D
5.1%
1Y
-22.6%